BioCentury
ARTICLE | Company News

Mylan launches first U.S. generic of GSK's Advair

February 15, 2019 8:04 PM UTC

Mylan N.V. (NASDAQ:MYL) launched Wixela Inhub salmeterol/fluticasone, the first generic version of Advair Diskus, in the U.S. at a list price 70% less than the branded version. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) markets Advair Diskus. Both treatments are indicated for asthma and chronic obstructive pulmonary disease (COPD).

Wixela Inhub has a wholesale acquisition cost of $93.71 for the 100 μg/50 μg dose, $116.44 for the 250 μg/50 μg dose and $153.14 for the 500 μg/50 μg dose. Mylan said Wixela Inhub costs 67% less than the authorized generic version GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched on Feb. 8...

BCIQ Company Profiles

GSK plc

Mylan N.V.